RxDoctor Payments Data

Nicola Calabrese, APRN

Acute Care · Middletown, CTNPI 1700155603

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,976 of the $9,164 with a category attached, or 65.2%. 7 manufacturers reported payments, led by Medtronic at 45.5% of the total. Reporting peaked in 2024 at $4,282 and has fallen 55.1% since, to $1,921 in 2025. Among acute care clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,164in general payments, 2019–2025

Across 122 payments — averaging $75.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Abbott$2K
  • Philips North America LLC$1K
  • Impulse Dynamics (USA) Inc.$879
  • Boston Scientific$878
  • Pfizer$123
  • plus $37 from 1 others

What the payments were for

  • Travel & lodging$3,18835%
  • Food & beverage$5,97665%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,164 in reported general payments places this provider in the 95th percentile of 239 acute care providers in Connecticut.

See all acute care providers in Connecticut

Medicare billing

Part B allowed, 2024
$22,813
Medicare patients
119
Services billed
298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$82,668
XareltoRivaroxaban25$36,945
Flecainide Acetate52$4,368
Amiodarone Hcl43$1,492
SotalolSotalol Hcl24$335
Metoprolol Succinate25$326
Amlodipine Besylate20$219
Metoprolol Tartrate17$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$123$82,66885 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 239 acute care providers in Connecticut.

Other acute care in Middletown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →